Form 4: Vaxart CMO's Routine Tax Withholding on RSU Vesting

Vaxart's Chief Medical Officer reported a routine disposition of shares to cover tax obligations related to RSU vesting.

Summary

• James F. Cummings, Chief Medical Officer of Vaxart, Inc. (VXRT), reported a transaction on March 18, 2026.
• The transaction involved the disposition of 6,772 shares of Vaxart Common Stock.
• These shares were withheld by Vaxart to satisfy income tax withholding and remittance obligations in connection with the net settlement of Restricted Stock Units (RSUs) that vested on March 18, 2026.
• The price per share for the disposed securities was $0.6346.
• Following this transaction, James F. Cummings beneficially owns 958,020 shares of Common Stock.
• The total beneficial ownership includes 75,618 shares acquired under the Vaxart, Inc. 2022 Employee Stock Purchase Plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. It is a routine administrative transaction for tax purposes related to RSU vesting and does not indicate a change in company fundamentals or management's outlook.

Future Outlook

NA

Industry Context

StockSavvy.ai notes this is a standard insider transaction for tax purposes, common across industries when restricted stock units vest. It reflects a routine administrative event rather than a discretionary sale or purchase.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction for tax purposes.

Key Dates

Recommendation

This Form 4 reports a routine disposition of shares by a company officer to cover tax obligations upon RSU vesting. It does not provide new fundamental information about Vaxart's operational performance or strategic direction, thus a 'hold' recommendation is maintained based solely on this filing.

Keywords

Vaxart, VXRT, Form 4, Insider Transaction, James F. Cummings, Chief Medical Officer, RSU Vesting, Tax Withholding, Common Stock, Employee Stock Purchase Plan